Halozyme Therapeutics (HALO) Shares are Down -2.63%

Halozyme Therapeutics (HALO) has risen sharply, recording gains of 8.01% in the past 4 weeks. However, the stock has corrected -2.63% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.6% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Halozyme Therapeutics, Inc. is up 9.07% in the last 3-month period. Year-to-Date the stock performance stands at -42.41%. The stock has recorded a 20-day Moving Average of 0.33% and the 50-Day Moving Average is 7.52%.


Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $9.96 on Friday but the bulls could not build on the opening and the stock topped out at $10.06 for the day. The stock traded down to $9.90 during the day, due to lack of any buying support eventually closed down at $9.98 with a loss of -0.20% for the day. The stock had closed at $10.00 on the previous day. The total traded volume was 702,912 shares.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.